Amish Dave, MD
Clinical Cardiac Electrophysiology · Houston, TXNPI 1861541922
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (39.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Abbott accounts for 67.6% of it on its own, with 27 other manufacturers making up the rest.
Across 601 payments — averaging $99.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$40K
- Medtronic$7K
- Biosense Webster, Inc.$4K
- Baylis Medical Company Inc$3K
- Boston Scientific$1K
- Angiodynamics, Inc.$891
- plus $3K from 22 others
Across 13 payments — averaging $5945.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Elutia, Inc.$64K
- Abbott$13K
What the payments were for
- Consulting fees$23,54839%
- Speaking & faculty fees$3,0005%
- Travel & lodging$13,18022%
- Food & beverage$19,69733%
- Education$2890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 234 | $40,374 |
| Medtronic(2 entities) | 188 | $6,680 |
| Biosense Webster, Inc. | 94 | $4,307 |
| Baylis Medical Company Inc | 1 | $3,000 |
| Boston Scientific | 30 | $1,245 |
| Angiodynamics, Inc. | 4 | $891 |
| Elutia, Inc. | 9 | $840 |
| Philips North America LLC | 3 | $609 |
| EBR Systems, Inc. | 1 | $255 |
| Volta Medical Inc | 2 | $244 |
| W. L. Gore & Associates, Inc. | 1 | $207 |
| Edwards Lifesciences | 2 | $179 |
| Medical Device Business Services, Inc. | 1 | $137 |
| Johnson & Johnson(2 entities) | 6 | $127 |
| Cardiva Medical, Inc. | 2 | $113 |
| Abiomed | 1 | $108 |
| E.r. Squibb & Sons, L.L.C. | 5 | $69 |
| Amgen | 2 | $54 |
| G Medical Diagnostic Services, Inc. | 1 | $46 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| Altathera Pharmaceuticals LLC | 2 | $32 |
| Tactile Systems Technology Inc | 2 | $32 |
| Lexicon Pharmaceuticals, Inc. | 1 | $27 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $26 |
| Pfizer | 2 | $26 |
| Biotronik Inc. | 2 | $25 |
| Cvrx, Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ensite Cardiac Mapping System$12,832
- TACTICATH ABLATION CATHETER, SENSOR ENABLED$9,679
- Advisor Catheter$8,524
- NRG needle$3,000
- Carto 3$2,306
- VIEWMATE$1,100
- EVERA MRI XT DR SURESCAN$1,027
- AVEIR$1,010
- TactiCath Quartz CFA Catheter$949
- AMPLATZER AMULET$867
- AngioVac$814
- COBALT DR MRI SURESCAN$804
- ECM Patch,Pouch$713
- EnSite Precision Cardiac Mapping System$689
- IGT Devices Und$609
- Assurity Pacemaker$474
- Micra$381
- AZURE XT DR MRI SURESCAN$297
- Fortify Assura, Ellipse ICD$293
- Accent Pacemaker$263
How this compares
$59,714 in reported general payments places this provider in the 70th percentile of 233 clinical cardiac electrophysiology providers in Texas.
See all clinical cardiac electrophysiology providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 534 | $510,652 |
| XareltoRivaroxaban | 42 | $61,162 |
| EntrestoSacubitril/Valsartan | 34 | $32,441 |
| Dofetilide | 64 | $11,436 |
| Metoprolol Succinate | 220 | $2,634 |
| Amiodarone Hcl | 61 | $2,395 |
| SotalolSotalol Hcl | 95 | $1,664 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 28 | $1,040 |
| Flecainide Acetate | 30 | $885 |
| Digoxin | 57 | $871 |
| Carvedilol | 51 | $570 |
| Sotalol AfSotalol Hcl | 39 | $522 |
| Metoprolol Tartrate | 46 | $433 |
| Losartan Potassium | 30 | $429 |
| Diltiazem Hcl | 13 | $417 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $26 | $510,652534 claims |
| Johnson & JohnsonXarelto | $127 | $61,16242 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 233 clinical cardiac electrophysiology providers in Texas.
Other clinical cardiac electrophysiology in Houston
- Miguel ValderrabanoHouston$461K
- Mehdi RazaviHouston$358K
- Ilyas ColombowalaHouston$204K
- Ramesh HariharanHouston$165K
- Nadim NasirHouston$162K
- John SegerHouston$147K
- Alexander DrtilHouston$126K
- Hamid Afshar-KharaghanHouston$112K
- David BurklandHouston$101K
- Jie ChengHouston$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.